COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,007 Articles (22,627 medRxiv, 8,380 bioRxiv)

Most recent first Previous |  Page 954: Articles 9531-9540  | Next

COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia
Barchuk, A., Bulina, A., Cherkashin, M., Berezina, N., Rakova, T., Kuplevatskaya, D., Stanevich, O., Skougarevskiy, D., Okhotin, A.
10.1101/2022.01.24.22269714 — Posted: 2022-01-24 Discussion: Onsite
Post-COVID-19 Memory Impairment: Prevalence and Associated Factors
Ahmed, M., Roy, S., Chowdhury, S., Islam, A. M. K., Akhter, S., Iktidar, M. A., Hawlader, M. D. H.
10.1101/2022.01.23.22269525 — Posted: 2022-01-24
Effectiveness of Pfizer-BioNTech Vaccine Against COVID-19 Associated Hospitalizations among Lebanese Adults >=75 years- Lebanon, April-May 2021
Farah, Z., Haddad, N., Abou El-Naja, H., Saleh, M., Mrad, P., Ghosn, N.
10.1101/2022.01.19.22269514 — Posted: 2022-01-24
Nasally-delivered interferon-{lambda} protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including Omicron
Chong, Z., Karl, C. E., Halfmann, P. J., Kawaoka, Y., Winkler, E. S., Yu, J., Diamond, M. S.
10.1101/2022.01.21.477296 — Posted: 2022-01-24 Discussion: Offsite
Significance of the RBD mutations in the SARS-CoV-2 Omicron: from spike opening to antibody escape and cell attachment
Hossen, M. L., Baral, P., Sharma, T., Gerstman, B. S., Chapagain, P. P.
10.1101/2022.01.21.477244 — Posted: 2022-01-24
The N764K and N856K mutations in SARS-CoV-2 Omicron S protein generate potential cleavage sites for SKI-1/S1P protease
maaroufi, H.
10.1101/2022.01.21.477298 — Posted: 2022-01-24
Bacteriophage-derived dsRNA exerts anti-SARS-CoV-2 activity in vitro and in Golden Syrian hamsters in vivo
Vaivode, K., Verhovcova, I., Skrastina, D., Petrovska, R., Kreismane, M., Lapse, D., Rubene, D., Kalnina, Z., Pjanova, D.
10.1101/2022.01.22.477073 — Posted: 2022-01-24
Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice
Tatham, L., Sharp, J., Kijak, E., Herriott, J., Neary, M., Box, H., Valentijn, A., Cox, H., Pertinez, H., Curley, P., Arshad, U., Rajoli, R. K., Rannard, S., Stewart, J., Owen, A.
10.1101/2022.01.23.477397 — Posted: 2022-01-24
SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
Bojkova, D., Rothenburger, T., Ciesek, S., Wass, M. N., Michaelis, M., Cinatl, J.
10.1101/2022.01.20.477067 — Posted: 2022-01-24
Host Chitinase 3-like-1 is a Universal Therapeutic Target for the Delta, Omicron and Other SARS-CoV-2 Viral Variants in COVID 19
Kamle, S., Ma, B., Lee, C. M., Schor, G., Lee, C. G., Elias, J. A.
10.1101/2022.01.21.477274 — Posted: 2022-01-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).